MAIA Biotechnology, Inc.
No enriched coverage for $MAIA in the last 7 days.
No SEC Form 4 filings for $MAIA in the last 30 days.
See all $MAIA insider activity →MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.
MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.
MAIA Biotechnology expanded its Phase 3 THIO-104 trial for Ateganosine, an investigational lung cancer treatment, into Spain and Portugal. The study aims to enroll 100 patients by 2026, with an interim analysis planned for 2027. MAIA's stock has traded between $0.87 and $3.19 in the past year, closing at $1.32 on Wednesday.
Recent MAIA coverage spans financial news, insider activity and regulation.
The enrollment milestones indicate continued progress in the NSCLC program, setting up a future data readout that could move the stock.
The enrollment progress signals continued trial momentum and may lift the stock as investors anticipate forthcoming data.
The trial expansion adds new patient enrollment sites, increasing the likelihood of reaching the 100‑patient dosing target by year‑end.
First U.S. patient dosing marks trial progression and may unlock further funding.
Positive milestone may boost stock on expectations of efficacy data and potential accelerated approval.
AlphAI scores every news story that mentions MAIA with an AI model for sentiment and relevance, and aggregates insider trades from MAIA Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.
1 min readMAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.
2 min readMAIA Biotechnology expanded its Phase 3 THIO-104 trial for Ateganosine, an investigational lung cancer treatment, into Spain and Portugal. The study aims to enroll 100 patients by 2026, with an interim analysis planned for 2027. MAIA's stock has traded between $0.87 and $3.19 in the past year, closing at $1.32 on Wednesday.
2 min readDataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readMAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.
2 min readOn September 15, 2026, 162 insider stock purchases were reported. Notable transactions include Cascade Investment buying 176,547 shares of Republic Services (RSG) for $39.4M, Tricor PMT25 Holdings buying 525,000 shares of CPI Card Group (PMTS) for $11.3M, and Devon Energy (DVN) CEO buying 3,913 shares for $199,876.
2 min readVitoc Vlad (Chief Executive Officer) purchased 73,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 ($0.10M total) on 2026-09-14.
1 min readGuerrero Ramiro purchased 37,595 shares of MAIA Biotechnology, Inc. (MAIA) at $1.32 on 2026-09-10.
1 min readUniverse Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readGuerrero Ramiro purchased 133,790 shares of MAIA Biotechnology, Inc. (MAIA) at an average of $1.38 ($1.35–$1.39, $0.18M total) across 3 trades over 2026-08-26 to 2026-08-28.
1 min read
